ArticleVirchows Archiv : an international journal of pathology2026
High‑Grade renal cell carcinoma with somatic BRCA2 mutation and biphasic morphology: an additional case expanding the morphological spectrum of an emerging RCC type.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Renal cell carcinoma (RCC) associated with BRCA2 mutation is an extremely rare but increasingly recognized tumor type with characteristic but variable morphological features and aggressive behavior. We report a new case of high‑grade RCC harboring a somatic BRCA2 mutation in a 69‑year‑old male presenting with painless gross hematuria. The tumor exhibited a complex admixture of solid papillary/alveolar, cribriform, and tubulocystic architectures with prominent eosinophilic nucleoli. A biphasic pattern was observed, with central nests of more bland clear cells forming rosette‑like structures around hyaline basement membrane material, a finding reminiscent of TFEB‑altered RCC. Immunohistochemically, the tumor showed a nonspecific immunophenotype with expression of PAX8, CD10, and vimentin, while other RCC‑associated markers were negative. SMARCB1/INI1, SDHB, and FH expression were retained. Targeted next‑generation sequencing confirmed a somatic BRCA2 truncating mutation and absence of alterations in VHL, MET, TSC1/2/MTOR, SDHx, FH, or MiTF genes. A review of all five previously reported BRCA2‑associated RCCs revealed that all six reported cases (including ours) shared certain features: mixed papillary and solid architecture, high‑grade cytology with prominent nucleoli, and absence of other RCC‑defining molecular drivers. Our case not only reinforces the previously reported features but also expands the morphological spectrum of BRCA2‑associated RCC, providing further evidence that this may represent a distinct subtype of RCC.
Indexed as
Identifiers
42151595What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.